Danish pharmaceutical company Novo Nordisk has appointed Camilla Sylvest (pictured right) as its executive vice president in charge of commercial strategy and corporate affairs.
At the helm of this new unit she will be responsible for the company’s corporate functions within marketing, market access, strategy, communications, stakeholder relations and sustainability.
Prior to her new role, Sylvest was the company’s senior vice president in charge of its Chinese operations since 2015.
Lars Fruergaard Jørgensen, president and CEO at Novo Nordisk, said: “During her more than 20 years in Novo Nordisk, Camilla has consistently delivered strong business results, fostered strong relations with stakeholders and demonstrated a natural ability to rally her organisations around key priorities.
“This makes me very confident in her ability to successfully drive our commercial strategies as well as our strategies 
for developing Novo Nordisk as a responsible corporation focused on the needs of the patients we serve.”
Additionally, Doug Langa (pictured left), senior vice president, head of North America operations and president of Novo Nordisk Inc, is promoted to executive vice president.
He joined the company in 2011 and has over 25 years’ experience in the pharmaceutical and medical device industry.
Both Sylvest and Langa will report to Jørgensen.